Mesoblast Overview
- Year Founded
-
2004
- Status
-
Public
- Employees
-
108
- Stock Symbol
-
MSB
- Investments
-
4
- Share Price
-
$1.14
- (As of Thursday Closing)
Mesoblast General Information
Description
Mesoblast Ltd is a commercial-stage biotechnology company engaged in developing and commercializing allogeneic (off-the-shelf) cellular medicines for severe inflammatory conditions. Its commercial product, Ryoncil (remestemcel-L-rknd), is FDA-approved for steroid-refractory acute graft-versus-host disease in pediatric patients. The company is also developing Ryoncil for additional inflammatory indications. Its rexlemestrocel-L platform is being developed for chronic low back pain associated with degenerative disc disease and chronic heart failure. The company operates as a single segment focused on its allogeneic cellular medicines platform.
Contact Information
Website
www.mesoblast.comCorporate Office
- 55 Collins Street
- Level 38
- Melbourne, Victoria 3000
- Australia
Corporate Office
- 55 Collins Street
- Level 38
- Melbourne, Victoria 3000
- Australia
Mesoblast Timeline
Mesoblast Stock Performance
As of 19-Nov-2026, Mesoblast’s stock price is $1.14. Its current market cap is $1.49B with 1.3B shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.14 | $1.19 | $1.13 - $2.22 | $1.49B | 1.3B | 3.2M |
Mesoblast Financials Summary
As of 30-Sep-2026, Mesoblast has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2026 30-Jun-2026 | FY 2025 30-Jun-2025 | FY 2024 30-Jun-2024 |
|---|---|---|---|---|
| EV | 1,995,991 | 1,745,106 | 1,465,805 | 795,155 |
| Revenue | 120,250 | 17,198 | 5,902 | |
| EBITDA | (34,803) | (79,676) | (65,138) | |
| Net Income | (57,500) | (102,142) | (87,956) | |
| Total Assets | 773,079 | 784,683 | 669,153 | |
| Total Debt | 127,334 | 128,157 | 118,923 |
Mesoblast Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Mesoblast Comparisons
Industry
Financing
Details
Mesoblast Competitors (37)
One of Mesoblast’s 37 competitors is BioCardia, a Formerly VC-backed company based in Sunnyvale, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| BioCardia | Formerly VC-backed | Sunnyvale, CA | ||||
| Minerva Neurosciences | Formerly VC-backed | Burlington, MA | ||||
| Orbsen Therapeutics | Formerly PE-Backed | Galway, Ireland | ||||
| Baliopharm | Venture Capital-Backed | Basel, Switzerland | ||||
| Capricor Therapeutics | Formerly VC-backed | San Diego, CA |
Mesoblast Patents
Mesoblast Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| JP-2022065132-A | How to treat or prevent respiratory illness | Active | 12-Dec-2012 | ||
| JP-2020097618-A | Methods for treating or preventing respiratory conditions | Pending | 12-Dec-2012 | ||
| JP-2024041904-A | Methods for treating or preventing respiratory conditions | Pending | 12-Dec-2012 | ||
| AU-2013360026-A1 | Methods of treating or preventing respiratory conditions | Active | 12-Dec-2012 | ||
| AU-2013360026-B2 | Methods of treating or preventing respiratory conditions | Active | 12-Dec-2012 | A61K35/28 |
Mesoblast Signals
Mesoblast Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Mesoblast Investments & Acquisitions (4)
Mesoblast’s most recent deal was a Merger/Acquisition with Provasculon. The deal was made on 20-Dec-2013.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Provasculon | 20-Dec-2013 | Merger/Acquisition | Drug Discovery | ||
| Osiris Therapeutics (Culture Expanded Mesenchymal Stem Cell Business) | 11-Oct-2013 | Merger/Acquisition | Buildings and Property | ||
| Angioblast Systems | 23-Dec-2010 | Merger/Acquisition | Biotechnology | ||
| Angioblast Systems | 20-Jan-2009 | Corporate | Biotechnology |
Mesoblast ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
34.59 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Mesoblast FAQs
-
When was Mesoblast founded?
Mesoblast was founded in 2004.
-
Where is Mesoblast headquartered?
Mesoblast is headquartered in Melbourne, Australia.
-
What is the size of Mesoblast?
Mesoblast has 108 total employees.
-
What industry is Mesoblast in?
Mesoblast’s primary industry is Drug Discovery.
-
Is Mesoblast a private or public company?
Mesoblast is a Public company.
-
What is Mesoblast’s stock symbol?
The ticker symbol for Mesoblast is MSB.
-
What is the current stock price of Mesoblast?
As of 19-Nov-2026 the stock price of Mesoblast is $1.14.
-
What is the current market cap of Mesoblast?
The current market capitalization of Mesoblast is $1.49B.
-
Who are Mesoblast’s competitors?
BioCardia, Minerva Neurosciences, Orbsen Therapeutics, Baliopharm, and Capricor Therapeutics are some of the 37 competitors of Mesoblast.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process